To ask the Secretary of State for Health and Social Care, how many oncology combination therapies have been assessed by NICE via the Single Technology Appraisal process; how many of those received a positive recommendation for routine NHS commissioning; and how many have been made available through the cancer drugs fund, over the last five years.

Since April 2015, the National Institute for Health and Care Excellence (NICE) has appraised 53 different cancer combinations. 21 are recommended; eight are optimised. 4 are recommended for use in the Cancer Drugs Fund (CDF); six are optimised for use in the CDF. 6 are not recommended. 12 appraisals were terminated as NICE did not receive a submission from the company.